Evaluation of the prevalence of new-onset musculoskeletal symptoms in patients hospitalized for severe SARS-CoV-2 infection during the first two COVID waves in France: A descriptive analysis of the clinical data warehouse of 39 hospitals in France - 19/11/22
, Pierre Pinson, Nathanael Beeker, Christian Roux
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Highlights |
• | Prevalence of musculoskeletal symptoms within 90days after COVID infection was 8.8%. |
• | Patients with musculoskeletal symptoms post-COVID infection were older and more comorbid (obesity, hypertension and diabetes). |
• | Patients with musculoskeletal symptom post-COVID were more likely to receive higher doses of corticosteroids, antivirals and immunosuppressors. |
Abstract |
Objective |
To determine the prevalence of musculoskeletal (MSK) symptoms appearing after a SARS-CoV-2 infection.
Methods |
This was an observational cohort based on data available at the Assistance publique–Hôpitaux de Paris (AP–HP) Clinical Data Warehouse (which includes data of more than 11 million patients treated in the 39 hospitals from AP–HP). The data collected included both ICD-10 codes in discharge summaries, and recurring wording expressions search on medical electronic documents. To be included in the analysis, patients had to have a positive RT-PCR for SARS-CoV-2 and be admitted in any department of AP–HP. Patients with previous history of any MSK condition were excluded. MSK conditions were considered if occurring up to 90days after the positive RT-PCR. Demographics and disease characteristics including treatment were compared in both groups (MSK yes/no) by t-test or Chi2 test, accordingly.
Results |
In total, 17,771 patients had a positive SARS-CoV-2 RT-PCR at APHP and were admitted in any department of AP–HP. Among them, 15,601 had no previous history of MSK condition and among them, 1370 (8.8%) presented with MSK symptoms after the viral infection. The most prevalent MSK symptoms were back pain (32.9%), followed by arthralgia (29.9%), radicular pain (20.2%) and arthritis (22.8%). Patients with MSK symptoms (MSK+) were older (67 y vs. 64 y, P<0.01), more frequently obese (29% vs. 25%, P=0.03), hypertensive (34% vs. 30%, P<0.01) and with diabetes (21% vs. 18%, P<0.01). Treatment for SARS-CoV-2 was slightly different in both groups, with higher corticosteroids (40.7% vs. 29.0%, P<0.01), antivirals (21.5% vs. 15.3%, P<0.01) and immunosuppressors (8.5% vs. 4.5%, P<0.01) prescription rates in the MSK+ group.
Conclusion |
MSK symptoms occurred in almost 9% of patients admitted to the hospital after a SARS-CoV-2 infection, particularly in older and more comorbid patients. Further analysis evaluating whether these symptoms remain over time are needed.
Il testo completo di questo articolo è disponibile in PDF.Keywords : SARS-COV-2, Musculoskeletal
Mappa
Vol 89 - N° 6
Articolo 105450- Novembre 2022 Ritorno al numero
Articolo precedente
- Risk of Parkinson's disease in a gout Mediterranean population: A case-control study
- Maria A. Pou, Francesc Orfila, Javier Pagonabarraga, Silvia Ferrer-Moret, Hector Corominas, Cesar Diaz-Torne
- Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort
- Shuhui Hu, Robert Terkeltaub, Mingshu Sun, Xiaopeng Ji, Zhiyuan Li, Zijing Ran, Yushuang Li, Hui Zhang, Wenyan Sun, Changgui Li, Jie Lu
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.